Carl Zeiss Meditec AG
XETRA:AFX
Carl Zeiss Meditec AG
XETRA:AFX
Price:
58.75
EUR
-3.05%
Market Closed
Market Cap:
5.3B
EUR
Balance Sheet
Balance Sheet Decomposition
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG
| Current Assets | 1.2B |
| Cash & Short-Term Investments | 39.5m |
| Receivables | 582.9m |
| Other Current Assets | 590m |
| Non-Current Assets | 2.2B |
| Long-Term Investments | 20.4m |
| PP&E | 353.8m |
| Intangibles | 1.7B |
| Other Non-Current Assets | 117.2m |
Balance Sheet
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG
Currency: EUR
Millions
Annual
| Sep-2015 | Sep-2016 | Sep-2017 | Sep-2018 | Sep-2019 | Sep-2020 | Sep-2021 | Sep-2022 | Sep-2023 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
13
|
9
|
4
|
7
|
23
|
6
|
7
|
8
|
11
|
20
|
|
| Cash |
13
|
9
|
4
|
7
|
23
|
6
|
7
|
8
|
11
|
20
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
4
|
1
|
0
|
0
|
0
|
0
|
28
|
19
|
|
| Total Receivables |
560
|
627
|
936
|
981
|
1 000
|
980
|
1 295
|
1 366
|
1 337
|
617
|
|
| Accounts Receivables |
185
|
189
|
195
|
192
|
206
|
165
|
321
|
414
|
421
|
438
|
|
| Other Receivables |
375
|
438
|
741
|
789
|
795
|
815
|
974
|
952
|
915
|
179
|
|
| Inventory |
189
|
208
|
234
|
248
|
268
|
286
|
286
|
383
|
520
|
537
|
|
| Other Current Assets |
14
|
13
|
29
|
14
|
13
|
18
|
16
|
35
|
40
|
19
|
|
| Total Current Assets |
776
|
857
|
1 208
|
1 251
|
1 304
|
1 291
|
1 604
|
1 792
|
1 912
|
1 212
|
|
| PP&E Net |
67
|
65
|
59
|
63
|
117
|
135
|
200
|
236
|
316
|
354
|
|
| PP&E Gross |
67
|
65
|
59
|
63
|
117
|
135
|
200
|
236
|
316
|
354
|
|
| Accumulated Depreciation |
97
|
107
|
116
|
134
|
164
|
185
|
180
|
223
|
232
|
262
|
|
| Intangible Assets |
45
|
54
|
68
|
74
|
144
|
145
|
154
|
240
|
259
|
707
|
|
| Goodwill |
164
|
165
|
174
|
186
|
338
|
327
|
329
|
430
|
416
|
983
|
|
| Note Receivable |
10
|
13
|
15
|
9
|
11
|
9
|
9
|
9
|
13
|
15
|
|
| Long-Term Investments |
0
|
0
|
19
|
0
|
5
|
4
|
7
|
11
|
21
|
20
|
|
| Other Long-Term Assets |
76
|
94
|
80
|
79
|
102
|
104
|
94
|
105
|
96
|
102
|
|
| Other Assets |
164
|
165
|
174
|
186
|
338
|
327
|
329
|
430
|
416
|
983
|
|
| Total Assets |
1 139
N/A
|
1 248
+10%
|
1 623
+30%
|
1 662
+2%
|
2 022
+22%
|
2 015
0%
|
2 396
+19%
|
2 823
+18%
|
3 033
+7%
|
3 393
+12%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
66
|
87
|
100
|
101
|
118
|
92
|
145
|
189
|
240
|
184
|
|
| Accrued Liabilities |
76
|
80
|
80
|
98
|
116
|
109
|
138
|
154
|
157
|
162
|
|
| Short-Term Debt |
3
|
23
|
6
|
16
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
3
|
3
|
3
|
4
|
15
|
16
|
19
|
22
|
22
|
27
|
|
| Other Current Liabilities |
95
|
94
|
127
|
61
|
91
|
81
|
145
|
175
|
143
|
196
|
|
| Total Current Liabilities |
243
|
286
|
316
|
280
|
340
|
298
|
448
|
539
|
562
|
569
|
|
| Long-Term Debt |
10
|
8
|
4
|
7
|
152
|
141
|
178
|
198
|
230
|
527
|
|
| Deferred Income Tax |
12
|
10
|
9
|
5
|
18
|
17
|
15
|
22
|
35
|
138
|
|
| Minority Interest |
44
|
53
|
26
|
21
|
19
|
19
|
18
|
15
|
13
|
15
|
|
| Other Liabilities |
77
|
93
|
53
|
55
|
96
|
109
|
77
|
33
|
33
|
103
|
|
| Total Liabilities |
385
N/A
|
450
+17%
|
408
-9%
|
369
-10%
|
624
+69%
|
583
-7%
|
737
+26%
|
808
+10%
|
873
+8%
|
1 352
+55%
|
|
| Equity | |||||||||||
| Common Stock |
81
|
81
|
89
|
89
|
89
|
89
|
89
|
89
|
89
|
89
|
|
| Retained Earnings |
705
|
458
|
555
|
632
|
745
|
809
|
1 000
|
1 214
|
1 406
|
1 486
|
|
| Additional Paid In Capital |
0
|
314
|
620
|
620
|
620
|
620
|
620
|
620
|
620
|
620
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
150
|
|
| Other Equity |
32
|
56
|
49
|
49
|
56
|
87
|
51
|
92
|
44
|
4
|
|
| Total Equity |
754
N/A
|
798
+6%
|
1 215
+52%
|
1 293
+6%
|
1 398
+8%
|
1 432
+2%
|
1 659
+16%
|
2 015
+21%
|
2 159
+7%
|
2 042
-5%
|
|
| Total Liabilities & Equity |
1 139
N/A
|
1 248
+10%
|
1 623
+30%
|
1 662
+2%
|
2 022
+22%
|
2 015
0%
|
2 396
+19%
|
2 823
+18%
|
3 033
+7%
|
3 393
+12%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
81
|
81
|
89
|
89
|
89
|
89
|
89
|
89
|
89
|
88
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
